Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000178 : The Cancer Genome Atlas (TCGA) Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above.
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs002295 : Cross-site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms of CIMAC-CIDC Network Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. Genomic summary results will be available only to CIMAC-CIDC network investigators, trial Principal Investigators IC Specific Access Term : and approved personnel as described by the CIMAC-CIDC guidelines (xxxxx://xxxxx-xxxxxxx.xxx/wp-content/uploads/2019/08/Guidelines-for-CIMAC-CIDC-Aug-20-2019.pdf) Acknowledgement Statement : Scientific and financial supports for the CIMAC-CIDC Network are provided through the National Cancer Institute (NCI) Cooperative Agreements U24CA224319 (to the Icahn School of Medicine at Mount Sinai CIMAC), U24CA224331 (to the Xxxx-Xxxxxx Cancer Institute CIMAC), U24CA224285 (to the University of Texas MD Xxxxxxxx Cancer Center CIMAC), U24CA224309 (to the Stanford University CIMAC), and U24CA224316 (to the CIDC at Xxxx-Xxxxxx Cancer Institute). This work is also supported by grants from the Lung SPORE P50CA070907, NIH CCSG Award (CA016672), MD Xxxxxxxx Cancer Center Support Grant (CA016672), National Cancer Institute under contract HHSN261200800001E. Additional support is made possible through the NCI CTIMS Contract HHSN261201600002C (to the Emmes Company, LLC). Scientific and financial supports for the PACT projects are made possible through funding support provided to the FNIH by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma GmbH & Co. KG., Xxxxxxx-Xxxxx Squibb, Celgene Corporation, Genentech Inc, Gilead, GlaxoSmithKline plc, Xxxxxxx Pharmaceutical Companies of Xxxxxxx & Xxxxxxx, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi. Name : General Research Use Consent Group # : 1 Abbreviation : GRU
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000340 : CREST: an algorithm that directly maps structural variants for next-generation sequencing data Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above.
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000206 : CGEMS Pancreatic Cancer (PanScan) Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), US National Institutes of Health (NIH) under contract number HHSN261200800001E. Additional support was received from NIH/NCI K07 CA140790, the American Society of Clinical Oncology Conquer Cancer Foundation, the Xxxxxx Xxxxxx Medical Institute, the Xxxxxxxxxx Foundation, the Xxxxxx X. and Xxxxxx X. Xxxx Fund for Acknowledgement Statement : Pancreatic Cancer Research and Promises for Purple. A full list of acknowledgments for each participating study is provided in the Supplementary Note of the manuscript with PubMed ID: 25086665. The datasets have been accessed through the NIH database for Genotypes and Phenotypes (dbGaP) under accession #phs000206. If these dataset(s) were used, please cite manuscripts with PubMed IDs: 25086665, 20101243, and 19648918 in all oral or written presentations, disclosures, or publication. Name : Cancer in all age groups, other diseases in adults only, and methods Consent Group # : 1 Abbreviation : CADM Data Use Limitation : The informed consent document signed by the PanScan GWAS participants allows use of these data by investigators for discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groups and other diseases in adults only, as well as development of novel analytical approaches for GWAS. Name : Disease-Specific (Pancreatic Cancer, GSO) Consent Group # : 2 Abbreviation : DS-PACA-GSO Data Use Limitation : Use of the data must be related to Pancreatic Cancer. Use of the data is limited to genetic studies only. Name : Disease-Specific (Pancreatic Cancer, IRB, COL, GSO) Consent Group # : 4 Abbreviation : O-DS-PACA-IRB-COL-GSO Use of the data must be related to Pancreatic Cancer.? Requestor must provide documentation of JHU IRB approval.? Requestor must provide a letter of collaboration with the primary study investigator(s).? Use of the data is limited to genetic studies only.? Requestor(s) should obtain the Xxxxx Xxxxxxx PanScan II Collaborator Agreement ...
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000007 : Framingham Cohort Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : National Heart, Lung, and Blood Institute DAC Important Contacts : xxxxxxxxxxxxxxxx@xxxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. DATA USE LIMITATION FOR FHS: Use of the Framingham data deposited in dbGaP is restricted to research on: genotype-phenotype associations; molecular phenotype (e.g., gene expression; microRNA)-phenotype associations; and proteomics/metabolomics-phenotype associations. All other phenotype-only analyses are prohibited (note: investigators may request data for such phenotype-only analyses through NHLBI’s BioLINCC). Additionally, the Framingham data may not be used to: o Investigate individual pedigree structures or individual participant genotypes for the purpose of identifying individuals or families; or explore issues such as non-maternity or non-paternity. IC Specific Access Term : o Investigate topics that could be considered as stigmatizing an individual or group. o Assess outcomes that are not related to health or disease conditions (note: methodological research that will serve as a prelude to health or disease research is permitted). Data users are responsible for ensuring that all uses of the data are consistent with federal, state, and local laws and any relevant institutional policies, and that the data are always maintained in a secured fashion. Data users will be required to obtain IRB approval for their projects from their respective institutions (please note that only full or expedited approvals will be accepted). It is anticipated that, at least in some cases, the FHS data will be updated with additional information and will be so identified by an appropriate version number. Data use is limited by consent groups to the following two groups: a) Health/Medical/Biomedical and related Methods and b) Health/Medical/Biomedical and related Methods for Non-Profit Use Only. Acknowledgement Statement : link Name : Health/Medical/Biomedical (IRB, MDS) Consent Group # : 1 Abbreviation : HMB-IRB-MDS Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor must provide documentation of local IRB approval. Use of the data includes m...
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000979 : HBCC Postmortem Psychiatric Molecular Studies Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : Joint Addiction, Aging, and Mental Health DAC Important Contacts : XXXXX-XXX@xxxx.xxx.xxx ; XXXXXXXXXXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above.
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., NIAGADS).
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000360 : eMERGE-I Genome Wide Association Studies of Network Phenotypes Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : National Human Genome Research Institute Important Contacts : xxxxxxxx@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. Acknowledgement Statement : Sample statements for the acknowledgment of the eMERGE GWAS dataset(s) can be found at the following link: eMERGE dbGaP Acknowledgment Statements (xxxx://xxx.xxxx.xxx.xxx.xxx/projects/gap/cgi-bin/GetPdf.cgi?document_name=eMERGE_Acknowledgement.pdf). Please include all Acknowledgment Statements relevant to the dataset(s) used in your analysis. Name : Health/Medical/Biomedical Consent Group # : 1 Abbreviation : HMB Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Data Use Limitation : These data will be used only for health related research, including research to improve methods for health related research. Name : Disease-Specific (Dementia) Consent Group # : 2 Abbreviation : DS-DEM Use of the data must be related to Dementia. Use of the data must be related to health research on dementia or other adult conditions related to the aging process. This includes research to improve methods for conducting research that could be applied to dementia or Data Use Limitation : other adult conditions related to the aging process. For example, studies of conditions like cataract, diabetes, and psoriasis might be appropriate, while conditions like attention deficit hyperactivity disorder (ADHD) and neuroblastoma might not be appropriate. Studies of conditions that are common in both children and the elderly, such as schizophrenia or depression, would not be appropriate if they focused on children or young adults. Studies focused primarily on pediatric populations are not permitted. Name : Health/Medical/Biomedical - Genetic Studies Only-No Insurance Companies Consent Group # : 3 Abbreviation : HM-B-GSO-NIC Data Use Limitation : Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Use of the data is limited to genetic studies only. No permitted use: Insurance Companies Name : Health/Medical/Biomedical (GSO) Consent Grou...
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000285 : CARDIA Cohort Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : National Heart, Lung, and Blood Institute DAC Important Contacts : xxxxxxxxxxxxxxxx@xxxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above.
Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000350 : CIDR Whole-exome sequencing in families with aggressive prostate cancer Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. Funding support for collection of the family-based data and samples for the Prostate Cancer Genetic Research Study (PROGRESS) was provided by grant RO1 CA080122 from the National Cancer Institute, NIH, with additional support provided by the Xxxx Xxxxxxxxxx Cancer Research Center and the Prostate Cancer Foundation. Data analysis was completed in collaboration with colleagues in the Department of Genome Sciences, University of Washington. Funding support for genotyping, which was performed at the Xxxxx Xxxxxxx Acknowledgement Statement : University Center for Inherited Disease Research, was provided by the NCI (XO1 HG006179). We also acknowledge the Intramural Program of the National Human Genome Research Institute and the Institute for Systems Biology. The datasets used for the analyses described in this manuscript were obtained from dbGaP found at xxxx://xxx.xxxx.xxx.xxx.xxx/projects/gap/cgi-bin/study.cgi?study_id=phs000350.v1.p1.
